Unit dosage forms for treatment of vasoconstriction and related conditions
US5849338A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 26, 1997 |
| Grant date | Dec 15, 1998 |
| Priority date | — |
| Expiry date | Aug 26, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Magnesium is formulated in combination with vitamin E, vitamin C, folate, selenium, and optionally melatonin in a unit dosage form for oral administration, for the treatment of vasoconstriction and the physiological and pathological conditions giving rise to vasoconstriction. These active agents complement each other in suppressing these conditions, using a variety of mechanisms operating in conjunction with one another. The inclusion of magnesium in a plurality of forms provides additional advantages in terms of controlling and sustaining the release of magnesium in locations along the digestive tract where the magnesium will have its greatest effectiveness as a therapeutic agent, thus improving control over thge clinical bioavailability of magnesium and in improving the selection of appropriate therapeutic ranges.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.